CardioDx, Inc., a Palo Alto, CA-based developer of cardiovascular genomic diagnostic solutions, has completed a $58m two-tranche equity financing.
Backers include Temasek and existing investors Longitude Capital, Artiman Ventures, Kleiner, Perkins, Caufield & Byers, J.P. Morgan, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Acadia Woods Partners, Bright Capital, the venture arm of RU-COM, Pappas Ventures, DAG Ventures, Asset Management Group, and GE Capital.
Led by David Levison, President and CEO, CardioDx is strategically focused on coronary artery disease, cardiac arrhythmia and heart failure and develops a clinically validated gene expression test for obstructive coronary artery disease called Corus® CAD.
The company intends to use the funding for the commercial expansion of Corus® CAD, and for development of additional genomic diagnostics in the field of cardiovascular disease.
Corus CAD is currently available in the United States.
CardioDx is currently hiring (http://www.cardiodx.com/about-cardiodx/careers).